Introduction
Nosocomial and community-acquired Gram-negative bacilli infections due to acquired carbapenemases are increasingly reported worldwide and the spread of carbapenem-resistant strains among hospitalized patients has become an increasing cause of concern [1, 2] . This phenomenon has an important impact in the duration of hospitalization, mortality rate, and health care costs [3] . Carbapenems (imipenem, meropenem, doripenem, aeruginosa. A novel insertion sequence ISPa8 discovered in the genome of Pseudomonas aeruginosa has a critical role in the insertional disruption in porin gene oprD [10] . In Klebsiella pneumoniae there are two major outer membrane porins, OmpK35/36, involved both in carbapenem resistance but also in virulence. In this particular case, porins deficiency is associated with virulence decrease associated only with ertapemen resistance [11, 12] . Another important mechanism involved in carbepenem resistance is the acquisition of gene-encoded carbapenemases. Furthermore, apart from transferable carbapenemases, it is well known that most important non-fermenters isolated from nosocomial infections (Acinetobacter spp. and Pseudomonas aeruginosa) have also chromosomal geneencoded AmpC-type cephalosporinase [13] . Functional and molecular characterization of carbapenemases, the most powerful beta-lactamases, is continuously reviewed due to the huge diversity of these enzymes [14, 15, 16, 17] . Carbapenemases are β-lactamases belonging to molecular Ambler class A (penicillinase), class B (metalloenzymes involved in natural resistance), and class D (oxacillinases) [18, 19, 20] . Even though class D carbapenemses are almost exclusively found in Acinetobacter spp., there are some reports of Pseudomonas aeruginosa clinical isolates that produce these type of beta-lactamases [21, 22] . Even though the amino acid sequences for some carbapenemeses are available, the source of the acquired carbapenemases remain unknown [23, 24, 25] . A recent study has shown a synergistic effect between the aztreonam and polyamines (spermine and spermidine) when carbapenem-resistant Acinetobacter spp. were tested [26] . A new challenge in the treatment of nosocomial infections arises from the emerging carbapenem-resistant strains. Antibiotic use is the main cause of evolution of antibiotic resistance and there is a real concern regarding the evolution of a resistance gene [27, 28] .
This study was undertaken to evaluate the extent of hospital-acquired infection with carbapenem-resistant strains in different clinical wards. The analysis of the data was limited to the comparison of the phenotypic patterns of four Gram-negative species: Acinetobacter spp., Pseudomonas aeruginosa, Escherichia coli, and Klebsiella spp. isolated from various clinical specimens.
Materials and methods

Bacterial strains and culture conditions
In this observational retrospective study we reviewed the microbiological data collected from the records of 540 individual patients hospitalized from January 2012 to November 2012 and from May 2013 to November 2013 in the County Emergency Clinical Hospital Cluj-Napoca. The patients were admitted in different hospital wards. Five hundred and sixty six strains (Acinetobacter spp., Pseudomonas aeruginosa, Escherichia coli, and Klebsiella spp.) were isolated. The collection included unique bacterial isolates and excluded duplicate isolates. Clinical strains were isolated from broncho-alveolar lavage, urine, peritoneal drainage, blood, wounds, catheter specimens, and other specimens. All specimens were inoculated on culture media: blood agar, MacConkey agar, Sabouraud media, and Chapman media. For urine samples CLED media was used as a selective culture media. All strains were identified according to their cultural appearance and their regular biochemical reactions.
Antimicrobial susceptibility
Non-fermentative isolates were tested for the following antibiotics: imipenem (10 mcg), meropenem (10 mcg), amikacin (30 mcg), gentamicin (10 mcg), ceftazidime (30 mcg), ciprofloxacin (5 mcg), cefoperazone/ sulbactam (75/30 mcg), piperacillin/tazobactam (100/10 mcg), and colistin (10 mcg). Enterobacteriaceae isolates were tested for: imipenem (10 mcg), meropenem (10 mcg), amikacin (30 mcg), gentamicin (10 mcg), ceftazidime (30 mcg), ciprofloxacin (5 mcg), and cefoperazone/sulbactam (75/30 mcg). The new CLSI standards do not have criteria for cefoperazone/sulbactam. To interpret cefoperazone/ sulbactam susceptibility, the zone of inhibition was compared with the breakpoints approved for cefoperazone [29, 30, 31] . Quality control strains E.coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were tested. Only 43 strains (11 strains of Acinetobacter spp., three strains of Pseudomonas aeruginosa, 11 strains of Escherichia coli, and 18 strains Klebsiella spp.) were also tested using VITEK-2 automatic system (BioMerieux) and the European Committee on Antimicrobial Susceptibility Testing. EUCAST served as a reference procedure (http://www. eucast.org) [32] . According to CLSI recommendation, carbapenem-resistant or carbapenem-intermediate strains were considered as non-susceptible to carbapenems.
Ethical statement All data collected in the present study were originated from our laboratory, therefore, the verbal or written consent of the patients was not obtained. However, before introducing and analyzing the data in our study, all identifiable data regarding the patients were removed.
Results
The 540 patients included in our study were hospitalized in 11 clinical wards: general surgery unit (213; 39.44%), anesthesia and intensive care unit (172; 25.92%), neurosurgery unit (29; 5.37%), neurosurgery intensive care unit (50; 9.25%), nephrology unit (57; 10.55%), internal medicine unit (9; 1.66%), gynecology unit (2; 0.37%), dermatology unit (3; 0.55%), orthopedic unit (3; 0.55%), oto-rhino-laryngology unit (1; 0.18%), and ophthalmology unit (1; 0.18%).
The It should be assumed that resistance to carbapenem is due to the impermeability of the membrane in addition to carbapemase production (oxa-or metallo-beta-lactamase). According to the Bush classification [16] class B metallobeta-lactamases do not hydrolyze aztreonam. In our [34] . CRE strains included in this study were not tested for aztreonam. The analysis of our data has revealed 43 cases of co-infections with carbapenem-resistant micro-organisms and other bacterial species. In figure 2 there are 33 cases of co-infection with carbapenem-resistant non-fermentative species and other bacterial or Candida species. We noticed the importance of infection due to Enterobacteriaceae species susceptible to carbapenems in association with carbapenem-resistant micro-organisms, therefore we took into consideration all the Enterobacteriaceae species isolated: E.coli, Proteus spp., Morganella spp. and Providencia spp. (data not shown).
A particular cause of concern is co-infection with two carbapenem-resistant species. Our data revealed seven (1.29%) cases of co-infection with carbapenemresistant Acinetobacter spp. and carbapenem-resistant P.aeruginosa. One patient (0.18%) was infected with CRE Klebsiella spp., carbapenem-resistant Acinetobacter spp., and methicillin resistant Staphylococcus aureus (MRSA). It is well known that Enterobacteriaceae play an important role in interspecies spreading of plasmids containing geneencoding carbapenemases. We noticed 11 (2.03%) patients with co-infection with carbapenem-resistant strains and Enterobacteriaceae susceptible to carbapenems.
Among the 191 isolates, Acinetobacter spp. was the most prevalent carbapenem-resistant organism; 154 (80.62%), 87 (45.54%) strains were isolated from anesthesia and intensive care units. Figure 3 shows the comparative distribution of carbapenem non-suceptible and carbapenem susceptible strains isolated from five health-care settings. 
Discussion
Early recognition and treatment of carbapenemresistant species must become a clinical priority for all hospitalized patients because resistance to carbapenems is often associated with resistance to other classes of antibiotics. Carbapenems as last-resort antibiotics recommended in eliminating ESBL-producing Enterobacteriaceae could no longer be a viable choice as monotherapy.
The number of appropriate antibiotics for the carbapenem-resistant micro-organisms infections is limited. Amikacin remains a viable option of treatment in some cases. Other authors recommend gentamycin instead [35] . In our study we did not identify any non-fermentative strains that exhibited resistance to colistin. In spite of its side effects [36, 37] , colistin had a remarkable antibiotic activity against carbapenem-resistant P.aeruginosa, its efficiency being even higher compared with a three-drug combination of aztreonam, ceftazidim and amikacin [38] . Colistin in combination with cefoperazone/sulbactam or tigecycline could have a synergistic effect against carbapenem-resistant Acinetobacter spp. [39] .
There are certain recommendations regarding the treatment of patients colonized or infected with carbapenem-resistant micro-organisms: single room ward, enhanced environmental cleaning during hospitalization, hospital-stay length, active surveillance of the patients transferred from countries or institutions with epidemic or endemic carbapenem-resistant Gram-negative strains occurrence [40, 41] . However, making a clear distinction between colonization and infection with carbapenemresistant strains could be a difficult task [42] .
There are several limitations to our study, including the lack of clinical information regarding the risk factors, treatment provided, days of hospitalization, and data regarding previous hospitalizations. In the clinical laboratory the accurate identification of carbapenem-resistant strains can be difficult to achieve due to methodological limitations, such as the availability of selective CRE agar [43] or Hodge test, although this test has a variable efficiency in detecting carbapenemase producing isolates [44] . However, the study has some strength such as the analysis of a sizeable quantity of strains, which allows to draw important conclusions regarding the dissemination and subsequent epidemics of carbapenem-resistant micro-organisms mainly in intensive care units. In addition, the phenotypic pattern of the strains isolated suggests that a combination of antimicrobial resistance mechanism contributes to the resistance to carbapenems used in therapy. Although some antibiotics are not constantly tested, aztreonam for example, we can still draw the same general conclusions about the genetic mechanisms involved in the resistance to carbapenems, based on the phenotypic patterns of the clinical isolates included in our study.
We assumed that among carbapenem-resistant strains, carbapenemase-producing strains are most commonly involved in infections following hospitalization of patients with severe illness. Molecular methods for accurate identification of carbapenem-resistant strains are not included in our clinical laboratory procedures. As a result, a reliable detection of the carbapenem-resistance mechanisms was not performed.
Conclusions
Surveillance of antimicrobial resistance in hospitals isolates provides useful guidelines for microbiologists and clinical practitioners, therefore accurate susceptibility testing is essential. All Gram-negative bacilli with a reduced susceptibility to meropenem or imipenem by disk diffusion method should be further tested for the production of carbapenemases. Patients hospitalized in intensive care units showed a trend toward higher risk of infections with carbapenem-resistant strains. Unlike Enterobacteriaceae, non-fermentative bacilli were much more frequently involved in maintaining and spreading of carbapenemresistant genes in hospital environment. Acinetobacter spp. as a major cause of hospital-acquired infection is a versatile bacteria which could develop very efficient resistance mechanisms under the selective pressure generated by antibiotic prescription.
